Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 5 % of short-term debt in 2025; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
Financials
Financial year 2025
PHARMA FUTUR from Thimister-Clermont, company number BE0787394827, closed financial year 2025 with a result of € -269,752 after tax. For that financial year PHARMA FUTUR recorded a gross margin of € 39,807 and equity of € -244,402. Compared with financial year 2024, the result moved from € 26,930 to € -269,752. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ -244,402
▼ € 269,752 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -269,752
▼ still € 26,930 profit in 2024
Profit after tax over the fiscal year.
€ 395
▼ 94% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -244,402.
People and assets in 2025
€ 178,420
▲ € 149,173 vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 44,498
▼ 22% vs 2024
Of which on lease € 3,589.
Debts at end 2025
€ 329,681
▲ € 304,304 vs 2024
€ 39,903 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 146,314
▼ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 73,479
▲ 142% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 24,149 | € -14,461 | € 103,582 | € 39,807 | ▼ 62% |
| Profit after taxes | € 22,451 | € -24,031 | € 26,930 | € -269,752 | ▼ € 296,682 |
| Equity | € 22,451 | € -1,580 | € 25,350 | € -244,402 | ▼ € 269,752 |
| Total debts | € 13,452 | € 13,016 | € 765,236 | € 873,696 | ▲ 14% |
| Cash | € 15,275 | € 986 | € 6,733 | € 395 | ▼ 94% |
| Retained profit | € 22,451 | € -1,580 | € 25,350 | € -244,402 | ▼ € 269,752 |
| Bank debt | € 0 | € 0 | € 25,377 | € 329,681 | ▲ € 304,304 |
| Balance sheet total | € 35,902 | € 11,436 | € 790,586 | € 629,295 | ▼ 20% |
Key figures of PHARMA FUTUR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA FUTUR?
What happened at PHARMA FUTUR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 269,752 (▼ € 296,682 vs 2024). Source: NBB ↗
- PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT SC became a director. NBB
- Pierre LAFLEUR became a director. NBB
- Marc DEVOGE stepped down as director. NBB
- Souad BARKANI stepped down as director. NBB
- Marc DEVOGE became a director. NBB
- New establishment in Liège. KBO
- Souad BARKANI became a director. NBB
In short
From € 22,451 profit in 2022 to € 269,752 loss in 2025.
Paid € 9,626 in corporate taxes since 2022.
Best year ever: 2024, with € 26,930 profit.
A new publication or filing at PHARMA FUTUR? We notify you, reason included.
Follow PHARMA FUTURDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMA FUTUR are PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT SC and Pierre LAFLEUR. PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT SC is also behind La Grande Pharmacie, Pharmacie du Perron, PHARMACIE LARDINOIS, SANTIS PHARMA and SANTIS GROUP.
Directors
According to the 2025 annual accounts
PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT SC
Director · represented by Hélène GORRIA
Also active at: La Grande Pharmacie, Pharmacie du Perron, PHARMACIE LARDINOIS, SANTIS PHARMA, SANTIS GROUP, Plate-Forme de Soins palliatifs de l'Est francophone, SOCIETE BEYNOISE DE PHARMACIE, V-IMMO +5 more
since 2026
Pierre LAFLEUR
Personne déléguée à la gestion journalière
since 2026
Souad BARKANI
Director
since 2022 · until 2025
since 2025 · until 2026
Establishments
Establishment units
Physical locations of this company
Rue de l'Avenir 12
4890 Thimister-Clermont
Avenue Maurice-Destenay 16
4000 Liège
Active since 17 June 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.
All companies at this address →PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT same network
€ 109.5 million revenue · 2025
La Grande Pharmacie same network
€ 54,296 revenue · 2025
PHARMACIE LARDINOIS same network
€ 49,909 revenue · 2025
SANTIS PHARMA same network
€ 17.9 million revenue · 2025
GENERATION 2000
€ 971,059 revenue · 2025
+3 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0787.394.827
- VAT number
- BE 0787.394.827
- Registered office
- Rue de l'Avenir 12, 4890 Thimister-Clermont
- Names & denominations
- PHARMA FUTUR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 June 2022
- Peppol
- Active · Active since 12 Jan 2026
- Activities · NACE
Overige zakelijke dienstverlening, neg
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige gespecialiseerde wetenschappelijke en technische activiteiten